Delving into the Latest Updates on Drossapharm AG with Synapse

Overview

Randomized, controlled, multi-center trial to evaluate the efficacy and safety of Lixim 70 mg wirkstoffhaltiges Pflaster (etofenamate 70 mg medicated plaster) vs. placebo in the local symptomatic and short-term treatment of pain in acute strains, sprains or bruises of soft tissues following blunt trauma, e.g. sports injuries

Start Date29 Dec 2021

Sponsor / Collaborator

Drossapharm AG

EUCTR2020-001032-99-DE

/ CompletedPhase 3

Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of “Lixim 70 mg wirkstoffhaltiges Pflaster” (etofenamate 70 mg medicated plaster) applied once daily (every 24 hours) or twice daily (every 12 hours) vs. matching placebo in the short-term symptomatic treatment of local pain in acute uncomplicated ankle sprains in adults

Start Date03 Sep 2020

Sponsor / Collaborator

Drossapharm AG

EUCTR2016-000252-99-DE

/ CompletedPhase 3

A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an etofenamate 5% cutaneous patch applied twice daily in subjects with acute uncomplicated unilateral ankle sprain for a period of 7 consecutive days.

Start Date08 Jun 2016

Sponsor / Collaborator

Drossapharm AG

100 Clinical Results associated with Drossapharm AG

Login to view more data

0 Patents (Medical) associated with Drossapharm AG

Login to view more data

100 Deals associated with Drossapharm AG

Login to view more data

100 Translational Medicine associated with Drossapharm AG

Login to view more data